Stabilis

Sodium Phosphate

Lösningars stabilitet

PVC		0,030 mmol/ml	23°C		63			3945
PVC		0,030 mmol/ml	4°C		63			3945
PVC		0,150 mmol/ml	23°C		63			3945
PVC		0,150 mmol/ml	4°C		63			3945

Stabilitet i blandningar

?		0,01 mmol/ml	25°C	?	Ampicillin sodium : 12 mg/ml	48	3880

Kompatibilitet

		Sodium Phosphate : 0,12 mmol/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Sodium Phosphate : 3 mmol/ml Caffeine : 10 mg/ml	∅	3964
		Sodium Phosphate Calcium gluconate		4964
		Sodium Phosphate		3945
		Sodium Phosphate		3945
		Sodium Phosphate Calcium gluconate		3644
		Sodium Phosphate : 3 mmol/ml		1415
		Sodium Phosphate : 3 mmol/ml Calcium gluconate : 100 mg/ml		789
		Sodium Phosphate : 0,5 mmol/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Sodium Phosphate : 0,5 mmol/ml Ceftaroline fosamil : 2,22 mg/ml		3249

		Sodium Phosphate : 0,5 mmol/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Sodium Phosphate Ceftobiprole medocaril sodium		4650
		Sodium Phosphate : 0.5 mmol/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Sodium Phosphate : 0.5 mmol/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Sodium Phosphate : 0.5 mmol/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Sodium Phosphate : 0,3 mmol/ml Ciprofloxacin lactate : 2 mg/ml	0.45	268
		Sodium Phosphate : 3 mmol/ml Ciprofloxacin lactate : 2 mg/ml		261
		Sodium Phosphate : 0.5 mmol/ml Doripenem : 5 mg/ml		2262
		Sodium Phosphate : 0.5 mmol/ml Fosfomycin : 30 mg/ml		4055
		Sodium Phosphate : 0.5 mmol/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Sodium Phosphate : 3 mmol/ml Lansoprazole : 0,55 mg/ml		1625
		Sodium Phosphate : 120 mmol/ml Magnesium sulfate : 150 mg/ml		4863
		Sodium Phosphate Magnesium sulfate		3838
		Sodium Phosphate : 3 mmol/ml Magnesium sulfate : 500 mg/ml		4389
		Sodium Phosphate : 3 mmol/ml Meropenem : 50 mg/ml		4319
		Sodium Phosphate : 0.5 mmol/ml Micafungin : 1.5 mg/ml		2108
		Sodium Phosphate : 0.5 mmol/ml Plazomicin sulfate : 24 mg/ml		4145
		Sodium Phosphate : 0,3 mmol/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Sodium Phosphate : 0.5 mmol/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Sodium Phosphate : 0.5 mmol/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Sodium Phosphate : 0.5 mmol/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Sodium Phosphate : 1 mmol/ml		301

Administreringssätt

Hänvisningar

	Typ	Publikation
261	tidningen	Percy LA, Rho JP. Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 715-716.
268	tidningen	Benjamin BE. Ciprofloxacin and sodium phosphate not compatible during actual Y-site injection. Am J Health-Syst Pharm 1996 ; 53: 1850-1851.
301	tidningen	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
789	tidningen	Garner SS, Wiest DB. Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system. Am J Hosp Pharm 1990 ; 47: 604-606.
1415	tidningen	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1611	tidningen	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	tidningen	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
2108	tidningen	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2262	tidningen	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	tidningen	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3249	tidningen	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	tidningen	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3644	Laboratorium	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3827	affisch	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	affisch	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	affisch	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015

3838	Laboratorium	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3880	tidningen	Maher M, Jensen Kara J,Lee David, Nix David E Stability of Ampicillin in Normal Saline and Buffered Normal Saline. Int J Pharm Compound 2016 ; 20, 4 : 338-342
3945	tidningen	Perks W, Iazzetta J, Chan P.C, Brouzas A, Law S,Walker S.E. Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags. Can J Hosp Pharm 2017 ; 70,1 : 7-12.
3964	tidningen	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	tidningen	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	tidningen	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	tidningen	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	tidningen	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4528	tidningen	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4650	Laboratorium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4801	tidningen	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4863	tidningen	Bautista S.C, Lozano I.J, Belles L.C, Parramón-Teixidó C.J, Esquerda C.G, Sanjuan A.P, Noves C.D, Encinas V.S, Maria Josep Caba Physical Compatibility Between Intravenous Magnesium Sulfate and Potassium or Sodium Phosphate in a Pediatric Intensive Care Unit. Hosp Pharm 2024 ; 59, 5:
4964	Laboratorium	GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit. B BRAUN MELSUNGEN AG 2019

Förklaringar

	elektrolyt		injektion
	Lösningars stabilitet		Behållare
	Molekyl		Koncentration
	Temperatur		Förvaring
	Stabilitets varaktighet		biologiskt likartat
	motstridiga uppgifter		Hänvisningar
PVC	Polyvinylklorid		NaCl 0,9 % eller glukos 5 %
	Ljus		Dag
	Stabilitet i blandningar		Lösningsmedel
	Substans	?	Ej angiven
	Natriumklorid 0,9 %	?	Ej angiven
	Timma		Kompatibilitet
	Omedelbar nederbörd		Oförenlig
	Glukos 5 %		Utfällning efter 4 timmar
∅	Ingen		Kompatibel
	Ospecificerad inkompatibilitet		Omedelbar instabilitet hos emulsionen
	Parenteral nutrition (med lipider)		Omedelbar grumlighet
RL	Ringer-laktatlösning		Utfällning efter 1 timme
0,45	Natriumklorid 0,45 %		Grumlighet på en timme
	Produktion av gasbubblor		Vatten för injektion
	Parenteral nutrition (binär blandning)		Administreringssätt
	Intravenös infusion		Långtidsinfusion
	Hänvisningar		Förklaringar